Yingjie Zhang

List of Publications by Citations

86 papers	1,372 citations	20 h-index	33 g-index
95 ext. papers	1,697 ext. citations	4.7 avg, IF	4.67 L-index

#	Paper	IF	Citations
86	A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. *Journal of Neuroinflammation*, **2019**, 16, 81	10.1	76
85	Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities. *Journal of Medicinal Chemistry*, **2011**, 54, 2823-38	8.3	75
84	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor. *Journal of Medicinal Chemistry*, **2015**, 58, 4325-38	8.3	61
83	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. *Journal of Medicinal Chemistry*, **2018**, 61, 5304-5322	8.3	57
82	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity. *Journal of Medicinal Chemistry*, **2014**, 57, 3324-41	8.3	56
81	Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 1761-72	3.4	53
80	Discovery of N-substituted oseltamivir derivatives as potent and selective inhibitors of H5N1 influenza neuraminidase. *Journal of Medicinal Chemistry*, **2014**, 57, 8445-58	8.3	50
79	The structure and function of histone deacetylases: the target for anti-cancer therapy. *Current Medicinal Chemistry*, **2008**, 15, 2840-9	4.3	49
78	Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. *Journal of Medicinal Chemistry*, **2011**, 54, 5532-9	8.3	48
77	Progress on Kinesin Spindle Protein Inhibitors as Anti-Cancer Agents. *Anti-Cancer Agents in Medicinal Chemistry*, **2008**, 8, 698-704	2.2	44
76	Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. *Journal of Medicinal Chemistry*, **2019**, 62, 3898-3923	8.3	38
75	Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. *Journal of Medicinal Chemistry*, **2018**, 61, 2589-2603	8.3	38
74	Development of -Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with Indole-Containing Cap Group. *ACS Medicinal Chemistry Letters*, **2013**, 4, 235-238	4.3	38
73	VEGF signal system: the application of antiangiogenesis. *Current Medicinal Chemistry*, **2014**, 21, 894-910	4.3	35
72	Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). *Expert Opinion on Therapeutic Patents*, **2020**, 30, 263-274	6.8	34
71	JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases. *Current Drug Targets*, **2018**, 19, 487-500	3	31
70	Progress of HDAC inhibitor panobinostat in the treatment of cancer. *Current Drug Targets*, **2014**, 15, 622-34	3	26

69	Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy. *Anti-Cancer Agents in Medicinal Chemistry*, **2017**, 17, 802-812	2.2	24
68	Synthesis and biological evaluation of N-(4-hydroxy-3-mercaptonaphthalen-1-yl)amides as inhibitors of angiogenesis and tumor growth. *European Journal of Medicinal Chemistry*, **2013**, 64, 377-88	6.8	23
67	Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1)-pyrazole Derivatives as JAKs Inhibitors. *ACS Medicinal Chemistry Letters*, **2016**, 7, 950-955	4.3	21
66	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study. *European Journal of Medicinal Chemistry*, **2017**, 134, 185-206	6.8	20
65	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 2981-2994	3.4	19
64	Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group. *European Journal of Medicinal Chemistry*, **2011**, 46, 5387-97	6.8	19
63	Discovery of BC-01, a novel mutual prodrug (hybrid drug) of ubenimex and fluorouracil as anticancer agent. *European Journal of Medicinal Chemistry*, **2016**, 121, 649-657	6.8	18
62	Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer. *Cancer Letters*, **2019**, 443, 1-12	9.9	18
61	Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 4481-4488	3.4	17
60	Progress on kinesin spindle protein inhibitors as anti-cancer agents. *Anti-Cancer Agents in Medicinal Chemistry*, **2008**, 8, 698-704	2.2	17
59	Discovery of a fluorescent probe with HDAC6 selective inhibition. *European Journal of Medicinal Chemistry*, **2017**, 141, 596-602	6.8	16
58	Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. *Molecules*, **2019**, 24,	4.8	16
57	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity. *Journal of Medicinal Chemistry*, **2020**, 63, 5501-5525	8.3	15
56	Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 150, 282-291	6.8	15
55	Design, synthesis and preliminary evaluation of □sulfonyl □(glycinyl-amino)proline peptidomimetics as matrix metalloproteinase inhibitors. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3055-64	3.4	15
54	Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 4437-44	3.4	15
53	Nitric oxide donor hybrid compounds as promising anticancer agents. *Drug Discoveries and Therapeutics*, **2017**, 10, 276-284	5	15
52	Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 2666-2675	3.4	14

51	Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 1487-95	3.4	14
50	Discovery of Novel Pyrrolo[2,3-]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors. *Journal of Medicinal Chemistry*, **2021**,	8.3	13
49	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity. *European Journal of Medicinal Chemistry*, **2015**, 89, 628-37	6.8	12
48	Development of N-hydroxybenzamide derivatives with indole-containing cap group as histone deacetylases inhibitors. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 6258-70	3.4	11
47	Enhanced anticancer activity of 5-FU in combination with Bestatin: Evidence in human tumor-derived cell lines and an H22 tumor-bearing mouse. *Drug Discoveries and Therapeutics*, **2015**, 9, 45-52	5	11
46	Synthesis and biological characterization of ubenimex-fluorouracil conjugates for anti-cancer therapy. *European Journal of Medicinal Chemistry*, **2018**, 143, 334-347	6.8	11
45	Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 5787-5795	3.4	10
44	Novel leucine ureido derivatives as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. *European Journal of Medicinal Chemistry*, **2016**, 108, 21-27	6.8	9
43	Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: synthesis and biological evaluation. Part II. *European Journal of Medicinal Chemistry*, **2013**, 69, 191-200	6.8	9
42	Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer. *Anti-Cancer Agents in Medicinal Chemistry*, **2018**, 18, 1241-1251	2.2	9
41	Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma. *Frontiers in Oncology*, **2020**, 10, 995	5.3	8
40	Design, Synthesis, and Biological Evaluation of Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors. *ChemMedChem*, **2018**, 13, 431-436	3.7	8
39	Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 3145-3157	3.4	7
38	Histone deacetylase inhibitors merged with protein tyrosine kinase inhibitors. *Drug Discoveries and Therapeutics*, **2015**, 9, 147-55	5	6
37	Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC. *Molecules*, **2020**, 25,	4.8	6
36	Design, synthesis and preliminary biological evaluation of 4-aminopyrazole derivatives as novel and potent JAKs inhibitors. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 2660-72	3.4	6
35	External-beam partial breast irradiation in a supine versus prone position after breast-conserving surgery for Chinese breast cancer patients. *Scientific Reports*, **2018**, 8, 15354	4.9	6
34	Leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry. Part II. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 978-990	3.4	5

33	Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. *Chemical Biology and Drug Design*, **2013**, 82, 125-30	2.9	5
32	Applications and modifications of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) in peptides and peptidomimetics design and discovery. *Current Protein and Peptide Science*, **2010**, 11, 752-8	2.8	5
31	Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU. *Medicinal Chemistry*, **2016**, 12, 30-6	1.8	5
30	Discovery of a series of novel compounds with moderate anti-hepatitis C virus NS3 protease activity in vitro. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 5539-45	3.4	4
29	Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 6632-40	3.4	4
28	Design, synthesis, and biological characterization of tamibarotene analogs as anticancer agents. *Chemical Biology and Drug Design*, **2016**, 88, 542-55	2.9	4
27	Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 454	5.7	4
26	A comparison of the location in membranes of curcumin and curcumin-derived bivalent compounds with potential neuroprotective capacity for Alzheimer's disease. *Colloids and Surfaces B: Biointerfaces*, **2021**, 199, 111525	6	4
25	Clinical investigation into the initial diagnosis and treatment of 539 patients with stage IV lung cancer. *OncoTargets and Therapy*, **2017**, 10, 535-541	4.4	3
24	3D QSAR and docking studies of a series of histone deacetylase inhibitors. *Medicinal Chemistry Research*, **2014**, 23, 2229-2241	2.2	3
23	Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold. *Drug Design, Development and Therapy*, **2015**, 9, 5553-67	4.4	3
22	Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. *Anti-Cancer Drugs*, **2014**, 25, 767-77	2.4	3
21	PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors. *Chemical Biology and Drug Design*, **2016**, 88, 574-84	2.9	3
20	Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. *Bioorganic Chemistry*, **2021**, 116, 105278	5.1	3
19	Potent Hydrazide-Based HDAC Inhibitors with a Superior Pharmacokinetic Profile for Efficient Treatment of Acute Myeloid Leukemia In Vivo.. *Journal of Medicinal Chemistry*, **2021**,	8.3	3
18	Setup Error Assessment and Correction in Planar kV Image- Versus Cone Beam CT Image-Guided Radiation Therapy: A Clinical Study of Early Breast Cancer Treated With External Beam Partial Breast Irradiation. *Technology in Cancer Research and Treatment*, **2019**, 18, 1533033819853847	2.7	2
17	Importin-4 functions as a driving force in human primary gastric cancer. *Journal of Cellular Biochemistry*, **2019**, 120, 12638-12646	4.7	2
16	Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study. *RSC Advances*, **2013**, 3,	3.7	2

15	Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 4614-4619	3.4	2
14	Postmastectomy radiotherapy using three different techniques: a retrospective evaluation of the incidental dose distribution in the internal mammary nodes. *Cancer Management and Research*, **2019**, 11, 1097-1106	3.6	2
13	Role of thyroglobulin in the management of patients with differentiated thyroid cancer. *Clinical and Translational Imaging*, **2019**, 7, 209-217	2	1
12	In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK-875. *Drug Development Research*, **2020**, 81, 708-715	5.1	1
11	Correlation Between Lung Density Changes Under Different Dose Gradients and Radiation Pneumonitis-Based on an Analysis of Computed Tomography Scans During Esophageal Cancer Radiotherapy. *Frontiers in Oncology*, **2021**, 11, 650764	5.3	1
10	Comparison of planning target volumes based on three-dimensional and four-dimensional CT imaging of thoracic esophageal cancer. *OncoTargets and Therapy*, **2016**, 9, 4785-91	4.4	1
9	Comparison of the Gross Target Volumes Based on Diagnostic PET/CT for Primary Esophageal Cancer. *Frontiers in Oncology*, **2021**, 11, 550100	5.3	1
8	Development of pyrazoline-based derivatives as aminopeptidase N inhibitors to overcome cancer invasion and metastasis.. *RSC Advances*, **2021**, 11, 21426-21432	3.7	1
7	Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. *Bioorganic Chemistry*, **2020**, 104, 104235	5.1	0
6	Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. *Investigational New Drugs*, **2021**, 1	4.3	0
5	Letter to the editor: Is it reasonable to prescribe RAI for all DTC patients with a primary tumor diameter exceeding 1□cm?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 2505-2506	8.8	
4	Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors.. *ACS Medicinal Chemistry Letters*, **2021**, 12, 1932-1941	4.3	
3	Comparison of biological target volume metrics based on FDG PET-CT and 4DCT for primary non-small-cell lung cancer. *Oncotarget*, **2017**, 8, 79629-79635	3.3	
2	Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy. *Bioorganic Chemistry*, **2021**, 116, 105343	5.1	
1	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.. *Bioorganic and Medicinal Chemistry Letters*, **2022**, 128797	2.9	